SKU: 615 Categories: , Tag:



It alleviates or eliminates manifestations of climacteric syndrome (sensation of heat, sweating, dizziness, irritability, depressive state), prevents the development of osteoporosis, prevents the involution of the genital organs, normalizes the menstrual cycle in women of childbearing age, lowers testosterone levels in men.

Contra-indications Premarin

– proven breast cancer or suspected of it;
– Proven estrogen-dependent neoplasms or suspicion of them;
Bleeding from the genital organs of an unknown genesis;
– Acute thrombophlebitis and thromboembolism (an indication of a history of the condition associated with the previous use of estrogens);
– Proven or presumptive pregnancy;
– Hypersensitivity to the components of the drug.

Side effect of Premarin

On the part of the reproductive system: the appearance of bloody discharge (of varying intensity), a change in the intensity of menstruation, amenorrhea.
From the digestive system: nausea, vomiting, flatulence, epigastric pain, cholestatic jaundice, pancreatitis.
On the part of the endocrine system: increase or decrease in body weight, increase in the size and tenderness of the mammary glands, the appearance of discharge from them, the change in libido.
From the side of the central nervous system: headache, dizziness, migraine, chorea.
From the side of the organ of vision: increased curvature of the cornea.
Dermatological reactions: melanosis (may persist after discontinuation of the drug), chloasma, alopecia, rash.
From the cardiovascular system: thromboembolism of veins, thromboembolism of the lungs.
Other: swelling, exacerbation of porphyria.

Dosing and Administration

Inside. For cyclic use – 625 mcg – 1.25 mg per day, alternating between reception for 3 weeks with a break of 1 week , menstrual bleeding begins with the 5th day of the menstrual cycle, and from the 15th to the 21st day in addition use a gestagenic Drug (with prolonged absence of menstruation, treatment is started any day). If necessary, on the 5th-7th day of treatment, the daily dose can be increased to 3.75 mg, then it is reduced to 1.25 mg. Treatment of malignant neoplasms is 3.75-7.5 mg.

Additional information